Melatonin Receptor Expression in Primary Uveal Melanoma
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25168711 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Anna Hagström und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neuroscience, Division of Eye and Vision, Karolinska Institutet, 171 77 Stockholm, Sweden. Hauptthemen laut MEDLINE: Uveal Neoplasms, Melanoma, Receptor, Melatonin, MT1, Nuclear Receptor Subfamily 1, Group F, Member 1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Karolinska Institutet, Region Stockholm, The Swedish Cancer Society.
Abstract (Originalsprache)
Melatonin, noted for its anti-cancer properties in various malignancies, including cutaneous melanoma, shows promise in Uveal melanoma (UM) treatment. This study aimed to evaluate melatonin receptor expression in primary UM and its association with UM-related mortality and prognostic factors. Immunohistochemical analysis of 47 primary UM tissues showed low expression of melatonin receptor 1A (MTNR1A) and melatonin receptor 1B (MTNR1B), with MTNR1A significantly higher in patients who succumbed to UM. Analysis of TCGA data from 80 UM patients revealed RNA expression for MTNR1A, retinoic acid-related orphan receptor alpha (RORα), and N-ribosyldihydronicotinamide:quinone oxidoreductase (NQO2), but not MTNR1B or G protein-coupled receptor 50 (GPR50). Higher MTNR1A RNA levels were observed in patients with a BRCA1 Associated Protein 1 (BAP1) mutation, and higher NQO2 RNA levels were noted in patients with the epithelioid tumor cell type. However, Kaplan–Meier analysis did not show distinct survival probabilities based on receptor expression. This study concludes that UM clinical samples express melatonin receptors, suggesting a potential mechanism for melatonin’s anti-cancer effects. Despite finding higher MTNR1A expression in patients who died of UM, no survival differences were observed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Neuroscience, Division of Eye and Vision, Karolinska Institutet, 171 77 Stockholm, Sweden.
- St. Erik Eye Hospital, 17164 Stockholm, Sweden.
- Ögonspecialisterna Farsta, 12347 Stockholm, Sweden.
ORCID-Profile: Anna Hagström, Ruba Kal Omar, Hans Witzenhausen, Gustav Stålhammar
Förderung
- Karolinska Institutet
- Region Stockholm
- The Swedish Cancer Society
- The Crown Princess Margareta Foundation for the Visually Impaired
- The Swedish Eye Foundation
- Gustav Stålhammar from: Region Stockholm
- Swedish Cancer Society
- Crown Princess Margareta Foundation for the Visually Impaired
Zitieren
APA
Hagström, A., Kal Omar, R., Witzenhausen, H., Lardner, E., Abdiu, O., & Stålhammar, G. (2024). Melatonin Receptor Expression in Primary Uveal Melanoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25168711
Vancouver
Hagström A, Kal Omar R, Witzenhausen H, Lardner E, Abdiu O, Stålhammar G. Melatonin Receptor Expression in Primary Uveal Melanoma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25168711
BibTeX
@article{Hagstrm2024,
author = {Hagström, Anna and Kal Omar, Ruba and Witzenhausen, Hans and Lardner, Emma and Abdiu, Oran and Stålhammar, Gustav},
title = {Melatonin Receptor Expression in Primary Uveal Melanoma},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25168711}
}
EUVIMED